<DOC>
	<DOC>NCT00890890</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.</brief_summary>
	<brief_title>A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient meets clinical criteria for prodromal Alzheimer's disease (MMSE 2430) Memory complaint by subject or study partner CSF aβ42 levels &lt; 200pg/mL or Total Tau/aβ42 ratio of ≥ 0.39 Score of ≤4 on the Modified Hachinski Ischemia Scale CT results consistent with Alzheimer's disease Medically stable 6 years education Reliable study partner Must be able to swallow capsules Premenopausal women DSMIV diagnosis of Dementia History of stroke Immunocompromised Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption Unstable Vitamin B12 deficiency Hematologic or solid malignancy within 5 years Geriatric Depression Scale ≥ 6 Unstable medical condition Alcohol or drug abuse history with 12months of study entry Significant drug allergy Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry Any other experimental therapy with 30days of study entry</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>